Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials

References

• Shukla AM, Wagle Shukla A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context. 2019 2019 Nov 25;8: 2019-9-1. Published doi: https://doi.org/10.7573/dic.2019-9-1
   Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
   Google Scholar
• Quiros Roldan E, Biasiotto G, Magro P, et al. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis? Pharmacol Res. 2020;158:104904.
   Google Scholar
• Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96(12):3484–3492.
   Google Scholar
• Savarino A, Shytaj IL. Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology. 2015 2015 Jun 18;12(1):51. . Published.
   Google Scholar
• De Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   Google Scholar
• Castelnuovo AD, Costanzo S, Antinori A, COVID-19 RISK and Treatments (CORIST) Collaboration. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study. Eur J Intern Med. 2020;82:38–47.
   Google Scholar
• Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22. Retracted article. doi: https://doi.org/10.1016/S0140-6736(20)31180-6
   Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. WHO Solidarity Trial Consortium,. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. .
   Google Scholar
• Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [retraction of: lancet. 2020 May 22]. Lancet. 2020;395(10240):1820.
   Google Scholar
• Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19–27.
   Google Scholar
• Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403.
   Google Scholar
• Catteau L, Dauby N, Montourcy M, et al. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents. 2020;56(4):106144.
   Google Scholar
• Horby P, Mafham M, Linsell L, et al. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–2040. .
   Google Scholar
• Albani F, Fusina F, Giovannini A, et al. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. J Clin Med. 2020 2020 Aug 30;9(9):2800. . Published.
   Google Scholar
• Ayerbe L, Risco-Risco C, Ayis S. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. Intern Emerg Med. 2020;15(8):1501–1506.
   Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [published correction appears in N Engl J Med. 2020 Nov 19;383(21):e119]. N Engl J Med. 2020;383(21):2041–2052.
   Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of Hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418.
   Google Scholar
• Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS One. 2020 2020 Aug 13;15(8):e0237693. . Published.
   Google Scholar
• Kalligeros M, Shehadeh F, Atalla E, et al. Hydroxychloroquine use in hospitalised patients with COVID-19: an observational matched cohort study. J Glob Antimicrob Resist. 2020;22:842–844.
   Google Scholar
• Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.
   Google Scholar
• Lammers AJJ, Brohet RM, Theunissen REP, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020;101:283–289.
   Google Scholar
• Lauriola M, Pani A, Ippoliti G, et al. Effect of combination therapy of Hydroxychloroquine and Azithromycin on mortality in patients with COVID-19. Clin Transl Sci. 2020;13(6):1071–1076.
   Google Scholar
• Lecronier M, Beurton A, Burrel S, et al. Comparison of hydroxychloroquine, lopinavir/ ritonavir,and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. Crit Care. 2020 2020 Jul 11;24(1):418. . Published.
   Google Scholar
• Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (N Y). 2020;1(1):114–127.e3. .
   Google Scholar
• Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data [published correction appears in BMJ. 2020 Jun 18;369:m2328]. BMJ. Published. 2020;369:m1844. 2020 May 14.
   Google Scholar
• Membrillo De Novales FJ, Ramírez-Olivencia G, Estébanez M, et al. Early Hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. Preprints. 2020;2020050057. DOI:https://doi.org/10.20944/preprints202005.0057.v1.
   Google Scholar
• Mikami T, Miyashita H, Yamada T, et al. Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med. 2021;36(1):17–26.
   Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a Randomized-Controlled trial [published online ahead of print, 2020 Jul 16]. Clin Infect Dis. 2020;ciaa1009. DOI:https://doi.org/10.1093/cid/ciaa1009.
   Google Scholar
• Paccoud O, Tubach F, Baptiste A, et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital [published online ahead of print, 2020 Jun 18]. Clin Infect Dis. 2020;ciaa791. doi: https://doi.org/10.1093/cid/ciaa791.
   Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with Hydroxychloroquine or Azithromycin with in-Hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–2502.
   Google Scholar
• Sbidian E, Josse J, Lemaitre G, et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. medRxiv. 2020 June 16;20132597. doi: https://doi.org/10.1101/2020.06.16.20132597.
   Google Scholar
• Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(21):2165–2176.
   Google Scholar
• Singh S, Khan A, Chowdhry M, et al. Outcomes of Hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States- Real-World evidence from a federated electronic medical record network. medRxiv. 2020 May 12; 20099028. doi: https://doi.org/10.1101/2020.05.12.20099028.
   Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623–631.
   Google Scholar
• Sulaiman T, Mohana A, Alawdah L, et al. The effect of early Hydroxychloroquine-based Therapy in COVID-19 patients in ambulatory care settings: a nationwide prospective cohort study. medRxiv. 2020 September 09;20184143. doi: https://doi.org/10.1101/2020.09.09.20184143.
   Google Scholar
• Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 [published correction appears in sci China life sci. Sci China Life Sci. 2020;63(10):1515–1521.
   Google Scholar
• Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the Treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103(4):1635–1639.
   Google Scholar
• Awad N, Schiller DS, Fulman M, et al. Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection [published online ahead of print, 2021 Feb 18]. Am J Health Syst Pharm. 2021;78(8):zxab056.
   Google Scholar
• Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219.
   Google Scholar
• Chen L, Zhang ZY, Fu JG, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. 2020 June 19;20136093. doi: https://doi.org/10.1101/2020.06.19.20136093.
   Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020 March 22;20040758. doi: https://doi.org/10.1101/2020.03.22.20040758.
   Google Scholar
• Dubée V, Roy PM, Vielle B, et al. A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19. medRxiv. 2020 October 19;20214940. doi: https://doi.org/10.1101/2020.10.19.20214940.
   Google Scholar
• Gonzalez JLB, González Gámez M, Mendoza Enciso EA, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. medRxiv. 2021;2:18.21252037.
   Google Scholar
• Hernandez-Cardenas C, Thirion-Romero I, Rivera-Martinez NE, et al. Hydroxychloroquine for the treatment of severe respiratory infection by covid-19: a randomized controlled trial. medRxiv. 2021. 02.01.21250371. doi: https://doi.org/10.1101/2021.02.01.21250371
   Google Scholar
• Kim EJ, Coppa K, Hirsch JS, et al. Examination of patient characteristics and hydroxychloroquine use based on the US food and drug administration’s recommendation: a cross-sectional analysis in New York. BMJ Open. 2021 2021 Feb 8;11(2):e042965. . Published.
   Google Scholar
• Lamback EB, Oliveira MA, Haddad AF, et al. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 [published online ahead of print, 2021 Feb 19]. Braz J Infect Dis. 2021;25(2):101549.
   Google Scholar
• Lotfy SM, Abbas A, Shouman W. Use of Hydroxychloroquine in patients with COVID-19: a retrospective observational study. Turk Thorac J. 2021;22(1):62–66.
   Google Scholar
• Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020 2020 Oct 20;11(1):5284. . Published.
   Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. Published. 2020;369:m1849. 2020 May 14.
   Google Scholar
• Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 with Hydroxychloroquine (TEACH): a Multicenter, Double-blind randomized controlled trial in hospitalized patients. Open Forum Infect Dis. 2020 2020 Sep 23;7(10):ofaa446. . Published.
   Google Scholar
• Moola S, Munn Z, Tufanaru C, et al. 7: systematic reviews of etiology and risk - Joanna briggs institute reviewers’ manual. Joanna Briggs Institute Reviewer’s Manual. 2017
   Google Scholar
• Berkman ND, Lohr KN, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the agency for healthcare research and quality: an update. Methods Guide for Comparative Effectiveness Reviews (Prepared by the RTI-UNC Evidence-based Practice Center under Contract No. 290-2007-10056-I). AHRQ Publication No. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm
   Google Scholar
• Ippolito MM, Flexner C. Dose optimization of Hydroxychloroquine for coronavirus infection 2019: do Blood concentrations matter? Clin Infect Dis. 2020;71(11):2965–2967.
   Google Scholar
• Plantone D, Koudriavtseva T. Current and future use of Chloroquine and Hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a Mini-Review. Clin Drug Investig. 2018;38(8):653–671.
   Google Scholar
• Wang C, Xie J, Zhao L, et al. Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19. Research Square. 26 Mar, 2020. doi: https://doi.org/10.21203/rs.3.rs-19346/v1
   Google Scholar
• McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-Like disease. Autoimmun Rev. 2020;19(6):102537.
   Google Scholar
• Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020–1022.
   Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–525.
   Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 2020 Mar 18;6(1):16. . Published.
   Google Scholar
• Schmidt RL, Jutz S, Goldhahn K, et al. Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. Sci Rep. 2017 2017 Feb 7;7(1):42191. . Published.
   Google Scholar
• Jankelson L, Karam G, Becker ML, et al. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm. 2020;17(9):1472–1479.
   Google Scholar
• Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2021;76(1):30–42.
   Google Scholar
• Kashour Z, Kashour T, Gerberi D, et al. . Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 Patients: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Transl Sci. 2021Feb19. doi: https://doi.org/10.1111/cts.13001 Epub ahead of print. PMID: 33606894; PMCID: PMC8013604
   Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015 Oct;23(5):231–269. . Epub 2015 Aug 6. PMID: 26246395.
   Google Scholar